It is also beginning to emerge that GSK-3β is mutated in approximately 1–4% of several tumor types (e.g., uterine endometrioid carcinoma, skin cancer, uterine neoplasms, melanoma, non-small-cell lung cancer, and cervical squamous cell carcinoma). Here, GSK3B is linked to neoplasm.